Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens

Journal of Immunotherapy

Volumn 24, Issue 3, 2001, Pages 232-236

  Lambert, Laura A ^a,b   Gibson, Glen R ^a,b   Maloney, Marybeth ^a,b   Richard Jr , J Barth ^a,b  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Tumor vaccine

Indexed keywords

TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNIZATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; SARCOMA CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROPIONIBACTERIUM ACNES; SARCOMA, EXPERIMENTAL;

EID: 0035005567     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200105000-00006     Document Type: Article

References (20)

1. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific imnunotherapy for stage II and stage III human colon cancer: a randomised trial [see comments]. Lancet 1999;353:345-50.
2. Hoover HC Jr, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy fur human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial [see comments]. J Clin Oncol 1993;11:390-9.
3. Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18:148-57.
4. Fields RC, Shimizu K, Mule JJ, Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95:9482-7.
5. Celluzzi CM, Falo LD Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998;160:3081-5.
6. Ronchetti A, Rovere P, Iezzi G, et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol 1999;163:130-6.
7. Earth RJ Jr, Mule JJ, Spiess PJ, Rosenbcrg SA, Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991;173:647-58.
8. Boisteau O, Gautier F, Cordel S, et al. Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 1997;2:403-12.
9. Lambert L, Gibson R, Maloncy M, et al. Intranodal immunization with tumor lysatc pulsed dendritic cells enhances anti-tumor immunity. Cancer Res 2001;61:641-6.
10. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 1966;36:641-5.
11. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156: 2918-26.
12. Geraghty PJ, Fields RC, Mule JJ. Vaccination with tumor-pulsed splenic dendritic cells mediates immunity to a poorly immunogenic tumor. Surg Forum 1996;47:459-61.
13. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor celltargeted gene transfer of interleukin 2, intedeukin 4, interleukin 7, tumor necrosis factor, or Interferon gamma. Proc Natl Acad Sci USA 1993;90:2774-8.
14. Shu SY, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 1985;45:1657-62.
15. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibilily complex class II compartment: downregulalion by cytokines and bacterial products [see comments]. J Exp Med 1995;182:389-400.
16. Inaba K, Turley S, Yamaide F, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998;188: 2163-73.
17. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
18. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9.
19. Rovere P, Vallinoto C, Bondanza A, el al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998;161:4467-71.
20. Henry F, Bretaudeau L, Barbieux I, Meflah K, Gregoire M. Induction of antigen presentation by macrophages after phagocytosis of tumor apoptotic cells. Rea Immunol 1998;149:673-9.